Clinical trial · Observational
Financial Toxicity in Patients With Early-stage Breast Cancer
Assessing Prevalence of Financial Burden and Impact of Cancer on Financial toxicIty in Patients With Early-stage Breast Cancer
NCT07354165CI-TRIAL-00101303VOICE - GIM36recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Non-profit, multicenter, prospective, observational study. This study aims to evaluate whether the articulated treatment algorithm that is now possible for early-stage breast cancer patients does produce tangible changes of financial distress over the time and whether the determinants of financial distress change their relative weight over the time.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Questionnaires | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (8)
- label
- Cohort 1
- description
- patients that received surgery without any further anticancer treatment
- interventionNames
- Other: Questionnaires
- label
- Cohort 2
- description
- patients that received surgery followed by adjuvant chemotherapy only
- interventionNames
- Other: Questionnaires
- label
- Cohort 3
- description
- patients that received surgery followed by chemotherapy and endocrine therapy
- interventionNames
- Other: Questionnaires
- label
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Signed informed consent form * Age \> 18 years at the time of study entry * Histologically confirmed stage I-III invasive breast carcinoma before starting any systemic treatment. Exclusion Criteria: * Stage IV invasive breast carcinoma * Major cognitive dysfunction or psychiatric disorders * Any previous systemic treatment for the current breast cancer
References
Publications (0)
Data not yet available
No reference posted for this study.